» Articles » PMID: 35221846

Does AGE-RAGE Stress Play a Role in the Development of Coronary Artery Disease in Obesity?

Overview
Journal Int J Angiol
Date 2022 Feb 28
PMID 35221846
Authors
Affiliations
Soon will be listed here.
Abstract

This article deals with the role of AGE (advanced glycation end products)-RAGE (receptor for AGE) stress (AGE/sRAGE) in the development of coronary artery disease (CAD) in obesity. CAD is due to atherosclerosis in coronary artery. The serum/plasma levels of AGE and sRAGE are reduced, while AGE-RAGE stress and expression of RAGE are elevated in obese individuals. However, the levels of AGE are elevated in obese individuals with more than one metabolic syndrome. The increases in the AGE-RAGE stress would elevate the expression and production of atherogenic factors, including reactive oxygen species, nuclear factor-kappa B, cytokines, intercellular adhesion molecule-1, vascular cell adhesion molecule-1, endothelial leukocyte adhesion molecules, monocyte chemoattractant protein-1, granulocyte-macrophage colony-stimulating factor, and growth factors. Low levels of sRAGE would also increase the atherogenic factors. The increases in the AGE-RAGE stress and decreases in the levels of sRAGE would induce development of atherosclerosis, leading to CAD. The therapeutic regimen for AGE-RAGE stress-induced CAD in obesity would include lowering of AGE intake, prevention of AGE formation, degradation of AGE in vivo, suppression of RAGE expression, blockade of AGE-RAGE interaction, downregulation of sRAGE expression, and use of antioxidants. In conclusion, the data suggest that AGE-RAGE stress is involved in the development of CAD in obesity, and the therapeutic interventions to reduce AGE-RAGE would be helpful in preventing, regressing, and slowing the progression of CAD in obesity.

Citing Articles

Pathological role of RAGE underlying progression of various diseases: its potential as biomarker and therapeutic target.

Sarkar S Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39589529 DOI: 10.1007/s00210-024-03595-6.


Implications of receptor for advanced glycation end products for progression from obesity to diabetes and from diabetes to cancer.

Garza-Campos A, Prieto-Correa J, Dominguez-Rosales J, Hernandez-Nazara Z World J Diabetes. 2023; 14(7):977-994.

PMID: 37547586 PMC: 10401444. DOI: 10.4239/wjd.v14.i7.977.

References
1.
Yamagishi S, Inagaki Y, Okamoto T, Amano S, Koga K, Takeuchi M . Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. J Biol Chem. 2002; 277(23):20309-15. DOI: 10.1074/jbc.M202634200. View

2.
Jia X, Wu L . Accumulation of endogenous methylglyoxal impaired insulin signaling in adipose tissue of fructose-fed rats. Mol Cell Biochem. 2007; 306(1-2):133-9. DOI: 10.1007/s11010-007-9563-x. View

3.
Prasad K, Dhar I, Zhou Q, Elmoselhi H, Shoker M, Shoker A . AGEs/sRAGE, a novel risk factor in the pathogenesis of end-stage renal disease. Mol Cell Biochem. 2016; 423(1-2):105-114. DOI: 10.1007/s11010-016-2829-4. View

4.
Reznikov L, Waksman J, Azam T, Kim S, Bufler P, Niwa T . Effect of advanced glycation end products on endotoxin-induced TNF-alpha, IL-1beta and IL-8 in human peripheral blood mononuclear cells. Clin Nephrol. 2004; 61(5):324-36. DOI: 10.5414/cnp61324. View

5.
Eilat-Adar S, Eldar M, Goldbourt U . Association of intentional changes in body weight with coronary heart disease event rates in overweight subjects who have an additional coronary risk factor. Am J Epidemiol. 2005; 161(4):352-8. DOI: 10.1093/aje/kwi045. View